However, in the restoration assay, ruxolitinib administered after treatment with IFN-γ was not enough to inhibit the effect of IFN-γ on the MHC class II molecule induction in mouse HFs (Figure 6). This evidence concerns the gene IFNG and Hand-foot syndrome.